Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy.

Hu YL, Jahangiri A, De Lay M, Aghi MK.

Autophagy. 2012 Jun;8(6):979-81. doi: 10.4161/auto.20232. Epub 2012 Jun 1.

2.

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Rohwer N, Cramer T.

Drug Resist Updat. 2011 Jun;14(3):191-201. doi: 10.1016/j.drup.2011.03.001. Epub 2011 Apr 3. Review.

PMID:
21466972
3.

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.

Rapisarda A, Melillo G.

Drug Resist Updat. 2009 Jun;12(3):74-80. doi: 10.1016/j.drup.2009.03.002. Epub 2009 Apr 25. Review.

4.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061178
5.

Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy.

Hu YL, Jahangiri A, Delay M, Aghi MK.

Cancer Res. 2012 Sep 1;72(17):4294-9. doi: 10.1158/0008-5472.CAN-12-1076. Epub 2012 Aug 22. Review.

6.

[Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].

Cohen-Jonathan Moyal E.

Cancer Radiother. 2009 Oct;13(6-7):562-7. doi: 10.1016/j.canrad.2009.07.007. Epub 2009 Aug 19. Review. French.

PMID:
19695923
7.

Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.

Shojaei F, Ferrara N.

Drug Resist Updat. 2008 Dec;11(6):219-30. doi: 10.1016/j.drup.2008.09.001. Epub 2008 Oct 23. Review.

PMID:
18948057
8.

Metabolic effects of anti-angiogenic therapy in tumors.

Zulato E, Curtarello M, Nardo G, Indraccolo S.

Biochimie. 2012 Apr;94(4):925-31. doi: 10.1016/j.biochi.2012.01.001. Epub 2012 Jan 11. Review.

PMID:
22245704
9.

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies.

Crawford Y, Ferrara N.

Trends Pharmacol Sci. 2009 Dec;30(12):624-30. doi: 10.1016/j.tips.2009.09.004. Review.

PMID:
19836845
10.

Anti-angiogenic therapies in cancer: achievements and open questions.

Ruegg C, Mutter N.

Bull Cancer. 2007 Sep;94(9):753-62. Review.

PMID:
17878094
11.

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality.

McIntyre A, Harris AL.

EMBO Mol Med. 2015 Feb 19;7(4):368-79. doi: 10.15252/emmm.201404271. Review.

12.

Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-angiogenesis for cancer therapeutics.

Li WW, Yu JY, Xu HL, Bao JK.

Biochem Biophys Res Commun. 2011 Oct 22;414(2):282-6. doi: 10.1016/j.bbrc.2011.09.072. Epub 2011 Sep 17. Review.

PMID:
21951850
13.

Inhibition of angiogenesis and the angiogenesis/invasion shift.

Bikfalvi A, Moenner M, Javerzat S, North S, Hagedorn M.

Biochem Soc Trans. 2011 Dec;39(6):1560-4. doi: 10.1042/BST20110710. Review.

PMID:
22103487
14.

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.

Rapisarda A, Melillo G.

Nat Rev Clin Oncol. 2012 Apr 24;9(7):378-90. doi: 10.1038/nrclinonc.2012.64. Review.

PMID:
22525710
15.

Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy.

Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA, Buttyan R.

Curr Drug Targets. 2003 Apr;4(3):191-6. Review.

PMID:
12643469
16.

Role of the tumor microenvironment in mediating response to anti-angiogenic therapy.

Jung YD, Ahmad SA, Akagi Y, Takahashi Y, Liu W, Reinmuth N, Shaheen RM, Fan F, Ellis LM.

Cancer Metastasis Rev. 2000;19(1-2):147-57. Review.

PMID:
11191054
17.

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Gotink KJ, Verheul HM.

Angiogenesis. 2010 Mar;13(1):1-14. doi: 10.1007/s10456-009-9160-6. Epub 2009 Dec 11. Review.

18.

Tumor angiogenesis and anti-angiogenic therapy.

Kubota Y.

Keio J Med. 2012;61(2):47-56. Review.

19.

Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression.

Cosse JP, Michiels C.

Anticancer Agents Med Chem. 2008 Oct;8(7):790-7. Review.

PMID:
18855580
20.

Interventions that induce modifications in the tumor microenvironment.

Bernhard EJ.

Cancer Radiother. 2011 Aug;15(5):376-82. doi: 10.1016/j.canrad.2011.01.007. Epub 2011 May 14. Review.

PMID:
21571567
Items per page

Supplemental Content

Write to the Help Desk